Related references
Note: Only part of the references are listed.Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study
An S. De Vriese et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies
Xin Liu et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Christoph Male et al.
LANCET HAEMATOLOGY (2020)
Comparison of Anticoagulants for Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Pilot Study
Todd W. Chapin et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2020)
Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke
Ken S. Butcher et al.
STROKE (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy
Jose Miguel Rivera-Caravaca et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis
Amr Shaaban Hanafy et al.
VASCULAR PHARMACOLOGY (2019)
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
H. -C. Diener et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis A Randomized Clinical Trial
Jose M. Ferro et al.
JAMA NEUROLOGY (2019)
Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants
Sri H. Kanuri et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation A Randomized Clinical Trial
Akihiko Nogami et al.
JAMA NETWORK OPEN (2019)
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
Michael D. Ezekowitz et al.
EUROPEAN HEART JOURNAL (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants
Z. Wolfe et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
R. G. Hart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use A Systematic Review and Meta-analysis
Wen-Yi Huang et al.
JAMA NEUROLOGY (2018)
Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials
George Ntaios et al.
INTERNATIONAL JOURNAL OF STROKE (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Hugh Calkins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy
Renato D. Lopes et al.
BLOOD (2017)
Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study
Taishi Kuwahara et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2016)
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
Andreas Goette et al.
LANCET (2016)
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis
Nicoletta Riva et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2016)
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)
Natalia S. Rost et al.
STROKE (2016)
A Meta-Analysis of Randomized Controlled Trials of the Risk of Bleeding With Apixaban Versus Vitamin K Antagonists
Lahoud Touma et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism Systematic Review and Meta-Analysis
Manuj Sharma et al.
CIRCULATION (2015)
Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence
Hein Heidbuchel et al.
EUROPACE (2015)
Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
Wei Du et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2015)
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
Agon Mekaj et al.
Therapeutics and Clinical Risk Management (2015)
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis
Daniel Caldeira et al.
JOURNAL OF NEUROLOGY (2015)
Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
Takeshi Fuji et al.
THROMBOSIS JOURNAL (2015)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman et al.
CIRCULATION (2014)
Pharmacology and Safety of New Oral Anticoagulants The Challenge of Bleeding Persists
Jerrold H. Levy
CLINICS IN LABORATORY MEDICINE (2014)
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
Riccardo Cappato et al.
EUROPEAN HEART JOURNAL (2014)
Edoxaban: a focused review of its clinical pharmacology
Gregory Y. H. Lip et al.
EUROPEAN HEART JOURNAL (2014)
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan
T. Fuji et al.
JOURNAL OF ARTHROPLASTY (2014)
Incidence, Mortality, and Risk Factors for Oral Anticoagulant-associated Intracranial Hemorrhage in Patients with Atrial Fibrillation
Rebbeca Grysiewicz et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2014)
Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
Graeme J. Hankey et al.
STROKE (2014)
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial
Takeshi Fuji et al.
THROMBOSIS RESEARCH (2014)
Safety and efficacy of edoxaban in patients undergoing hip fracture surgery
Takeshi Fuji et al.
THROMBOSIS RESEARCH (2014)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation
Lizheng Mao et al.
VASCULAR (2014)
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
Sebastian Harder et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients REPLY
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation
Takeshi Yamashita et al.
CIRCULATION JOURNAL (2012)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
Graeme J. Hankey et al.
LANCET NEUROLOGY (2012)
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial
J. Donald Easton et al.
LANCET NEUROLOGY (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran The RE-LY Trial
Robert G. Hart et al.
STROKE (2012)
Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation - The ARISTOTLE-J Study
Satoshi Ogawa et al.
CIRCULATION JOURNAL (2011)
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Samuel Z. Goldhaber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation
Namsik Chung et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (vol 9, pg 1157, 2010)
H. C. Diener et al.
LANCET NEUROLOGY (2011)
The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS)
Dominique A. Cadilhac et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2010)
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Michael Rud Lassen et al.
LANCET (2010)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
Hans Chnstoph Diener et al.
LANCET NEUROLOGY (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Quality-Adjusted Life Expectancy (QALE) and Loss of QALE for Patients With Ischemic Stroke and Intracerebral Hemorrhage A 13-Year Follow-Up
Hsin-Yi Lee et al.
STROKE (2010)
Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Jeffrey S. Ginsberg et al.
JOURNAL OF ARTHROPLASTY (2009)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Alexander G. G. Turpie et al.
LANCET (2009)
Six-Year Survival and Causes of Death among Stroke Patients in Korea
Hyeon Chang Kim et al.
NEUROEPIDEMIOLOGY (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar et al.
LANCET (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Dabigatran with or without concomitant Aspirin compared with Warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
Michael D. Ezekowitz et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial
B. I. Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson et al.
LANCET (2007)
Death and disability from warfarin-associated intracranial and extracranial hemorrhages
Margaret C. Fang et al.
AMERICAN JOURNAL OF MEDICINE (2007)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Update on intracerebral haemorrhage
Jose M. Ferro
JOURNAL OF NEUROLOGY (2006)
Avoiding central nervous system bleeding during antithrombotic therapy recent - Data and ideas
RG Hart et al.
STROKE (2005)
Share Paper
